Bavarian Nordic Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Public

  • Employees
  • 1,861

Employees

  • Stock Symbol
  • BAVA

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $36.43
  • (As of Thursday Closing)

Bavarian Nordic General Information

Description

Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Philip Heymans Alle 3
  • 2900 Hellerup
  • Denmark
+45 33
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
CSE
Vertical(s)
Corporate Office
  • Philip Heymans Alle 3
  • 2900 Hellerup
  • Denmark
+45 33

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bavarian Nordic Stock Performance

As of 19-Nov-2026, Bavarian Nordic’s stock price is $36.43. Its current market cap is $2.72B with 74.6M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$36.43 $35.74 $26.27 - $38.42 $2.72B 74.6M 216K $3.86

Bavarian Nordic Financials Summary

As of 30-Sep-2026, Bavarian Nordic has a trailing 12-month revenue of $987M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,185,000 1,905,585 1,834,288 1,845,472
Revenue 987,023 943,371 829,165 1,024,870
EBITDA 309,248 376,147 235,834 305,047
Net Income 139,425 207,800 143,311 214,076
Total Assets 2,284,228 2,351,749 2,009,859 2,131,049
Total Debt 18,642 20,581 17,893 21,573
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bavarian Nordic Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bavarian Nordic‘s full profile, request access.

Request a free trial

Bavarian Nordic Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization
Drug Discovery
Hellerup, Denmark
1,861 As of 2026

Basel, Switzerland
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bavarian Nordic Competitors (31)

One of Bavarian Nordic’s 31 competitors is Novartis, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland
Cipla Corporation Mumbai, India
Takeda Pharmaceutical Corporation Tokyo, Japan
Astellas Pharma Corporation Tokyo, Japan
OncBioMune Pharmaceuticals Corporate Backed or Acquired Baton Rouge, LA
You’re viewing 5 of 31 competitors. Get the full list »

Bavarian Nordic Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bavarian Nordic Investments & Acquisitions (4)

Bavarian Nordic’s most recent deal was a Merger/Acquisition with Emergent BioSolutions (Travel Vaccines) for . The deal was made on 15-Feb-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Emergent BioSolutions (Travel Vaccines) 15-Feb-2023 Merger/Acquisition Drug Discovery
GlaxoSmithKline (two travel vaccines) 31-Dec-2019 Corporate Asset Purchase Buildings and Property
Applied Process Company 27-Sep-2018 Corporate Other Pharmaceuticals and Biotechnology
BN ImmunoTherapeutics 11-Nov-2009 Corporate Drug Discovery
To view Bavarian Nordic’s complete investments and acquisitions history, request access »

Bavarian Nordic ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

20.99 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Bavarian Nordic’s complete esg history, request access »

Bavarian Nordic Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Bavarian Nordic Sweden Helsingborg, Sweden 2021
Aktieselskabet Af 1. Juni 2011 I Hellerup, Denmark 2011

Bavarian Nordic FAQs

  • When was Bavarian Nordic founded?

    Bavarian Nordic was founded in 1992.

  • Where is Bavarian Nordic headquartered?

    Bavarian Nordic is headquartered in Hellerup, Denmark.

  • What is the size of Bavarian Nordic?

    Bavarian Nordic has 1,861 total employees.

  • What industry is Bavarian Nordic in?

    Bavarian Nordic’s primary industry is Drug Discovery.

  • Is Bavarian Nordic a private or public company?

    Bavarian Nordic is a Public company.

  • What is Bavarian Nordic’s stock symbol?

    The ticker symbol for Bavarian Nordic is BAVA.

  • What is the current stock price of Bavarian Nordic?

    As of 19-Nov-2026 the stock price of Bavarian Nordic is $36.43.

  • What is the current market cap of Bavarian Nordic?

    The current market capitalization of Bavarian Nordic is $2.72B.

  • What is Bavarian Nordic’s current revenue?

    The trailing twelve month revenue for Bavarian Nordic is $987M.

  • Who are Bavarian Nordic’s competitors?

    Novartis, Cipla, Takeda Pharmaceutical, Astellas Pharma, and OncBioMune Pharmaceuticals are some of the 31 competitors of Bavarian Nordic.

  • What is Bavarian Nordic’s annual earnings per share (EPS)?

    Bavarian Nordic’s EPS for 12 months was $3.86.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process